GURUFOCUS.COM » STOCK LIST » Asia » China » SZSE » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » EV-to-EBITDA
Switch to:

China National Accord Medicines (SZSE:000028) EV-to-EBITDA

: 8.29 (As of Today)
View and export this data going back to 1993. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, China National Accord Medicines's enterprise value is ¥18,364 Mil. China National Accord Medicines's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was ¥2,216 Mil. Therefore, China National Accord Medicines's EV-to-EBITDA for today is 8.29.

The historical rank and industry rank for China National Accord Medicines's EV-to-EBITDA or its related term are showing as below:

SZSE:000028' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.64   Med: 13.26   Max: 31.96
Current: 8.1

During the past 13 years, the highest EV-to-EBITDA of China National Accord Medicines was 31.96. The lowest was 6.64. And the median was 13.26.

SZSE:000028's EV-to-EBITDA is ranked better than
54.17% of 72 companies
in the Medical Distribution industry
Industry Median: 9.13 vs SZSE:000028: 8.10

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2023-03-20), China National Accord Medicines's stock price is ¥47.96. China National Accord Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was ¥3.060. Therefore, China National Accord Medicines's PE Ratio for today is 15.67.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


China National Accord Medicines EV-to-EBITDA Historical Data

The historical data trend for China National Accord Medicines's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.44 7.32 5.60 6.07 5.36

China National Accord Medicines Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.38 5.36 8.38 7.35 6.86

Competitive Comparison

For the Medical Distribution subindustry, China National Accord Medicines's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

China National Accord Medicines EV-to-EBITDA Distribution

For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where China National Accord Medicines's EV-to-EBITDA falls in comparison to its industry or sector. The grey bar indicates the EV-to-EBITDA's extreme value range as defined by GuruFocus.



China National Accord Medicines EV-to-EBITDA Calculation

China National Accord Medicines's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=18363.905/2215.824
=8.29

China National Accord Medicines's current Enterprise Value is ¥18,364 Mil.
China National Accord Medicines's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,216 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China National Accord Medicines  (SZSE:000028) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

China National Accord Medicines's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=47.96/3.060
=15.67

China National Accord Medicines's share price for today is ¥47.96.
China National Accord Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3.060.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


China National Accord Medicines EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Accord Medicines (SZSE:000028) Business Description

China National Accord Medicines logo
Traded in Other Exchanges
Address
No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.

China National Accord Medicines (SZSE:000028) Headlines

No Headlines